Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Aron Gewirtzman

Dermatology Wilmington, NC Medical Doctor

NPI 1043478761 CMS profile 183933

1705 Gardner Road, Wilmington, NC 28405

Open in the dashboard

General payments

$17,238

575 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$235,967 paid to institutions, not to them · program years 2019–2023

Through program year 2023, Aron Gewirtzman of Wilmington, NC is reported in the CMS Open Payments database as having received $17,238 across 575 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $235,967 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 87th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $366 18
2022 General $7,305 152
2021 General $2,582 110
2020 General $2,011 144
2019 General $4,973 151

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aron Gewirtzman
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Aron Gewirtzman were reported at $0. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Aron Gewirtzman Dermatology median Middle half National median
2019 $4,973 $454 $129–$1,240 $163
2020 $2,011 $235 $81–$756 $114
2021 $2,582 $377 $108–$1,108 $132
2022 $7,305 $514 $143–$1,391 $149
2023 $366 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $0 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AbbVie, Inc. $6,006 66 payments
  2. Pfizer Inc. $2,894 38 payments
  3. Janssen Biotech, Inc. $1,281 107 payments
  4. Almirall LLC $818 2 payments
  5. Mayne Pharma Inc. $716 51 payments
  6. UCB, Inc. $674 31 payments
  7. Genzyme Corporation $621 31 payments
  8. VYNE Pharmaceuticals Inc. $594 38 payments
  9. Regeneron Healthcare Solutions, Inc. $590 28 payments
  10. Novartis Pharmaceuticals Corporation $524 25 payments
  11. Other $2,519 158 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $9,527 559 payments
  2. Consulting Fee $5,688 3 payments
  3. Travel and Lodging $1,639 6 payments
  4. Education $384 7 payments
Products named General payments · program years 2019–2023
  1. BOTOX $2,300 1 payment
  2. Klisyri $800 1 payment
  3. TREMFYA $782 58 payments
  4. SKYRIZI $687 41 payments
  5. Cimzia $674 31 payments
  6. DUPIXENT $590 28 payments
  7. HUMIRA $549 28 payments
  8. SIMPONI ARIA $499 49 payments
  9. STELARA $499 49 payments
  10. REMICADE $499 49 payments
  11. Other $7,236 487 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

575 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record